Search - tctmd.com

Displaying 741 - 760 of 8902

Sort: Relevancy | Date

MACE in CV Trials: Has the Outcome Outlived Its Role?

News Conference News EACTS 2024

MACE in CV Trials: Has the Outcome Outlived Its Role?

Yael L. Maxwell

October 11, 2024

Small Fraction of STEMI Patients With Shock Meet DanGer Criteria

News Daily News

Small Fraction of STEMI Patients With Shock Meet DanGer Criteria

October 11, 2024

Will Semaglutide Change Cardiac Surgery? It Already Has

News Conference News EACTS 2024

Will Semaglutide Change Cardiac Surgery? It Already Has

Yael L. Maxwell

October 10, 2024

APPRAISE ATP Highlights the Trade-offs of Antitachycardia Pacing

News Daily News

APPRAISE ATP Highlights the Trade-offs of Antitachycardia Pacing

October 09, 2024

Low CV Risk With ‘Living’ Cancer Therapies, Meta-analysis Shows

News Daily News

Low CV Risk With ‘Living’ Cancer Therapies, Meta-analysis Shows

October 09, 2024

Different Guidelines for Acute PE Offer a Mixed Bag of Advice

News Daily News

Different Guidelines for Acute PE Offer a Mixed Bag of Advice

October 08, 2024

Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM

News Conference News HFSA 2024

Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM

October 04, 2024

EXPANDed: Atrial Secondary MR Patients Get Clinical Benefit From TEER

News Conference News HFSA 2024

EXPANDed: Atrial Secondary MR Patients Get Clinical Benefit From TEER

October 03, 2024

‘Metabolic Accelerator’ Cuts Weight, Not Muscle in HFpEF: HuMAIN-HF

News Conference News HFSA 2024

‘Metabolic Accelerator’ Cuts Weight, Not Muscle in HFpEF: HuMAIN-HF

Michael O'Riordan

October 03, 2024

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

News Conference News HFSA 2024

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

October 02, 2024

FDA Approves First New PET Imaging Tracer for Cardiac Testing in Decades

News Daily News

FDA Approves First New PET Imaging Tracer for Cardiac Testing in Decades

October 02, 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

News Conference News HFSA 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

Michael O'Riordan

October 02, 2024

TCTMD’s Top 10 Most Popular Stories for September 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2024

October 01, 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

News Conference News HFSA 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

October 01, 2024

Deprescribing Antihypertensives May Slow Cognitive Decline in Nursing Home Patients

News Daily News

Deprescribing Antihypertensives May Slow Cognitive Decline in Nursing Home Patients

September 27, 2024

CVD Risk Twofold Higher in Patients With Cancer: ASPREE

News Daily News

CVD Risk Twofold Higher in Patients With Cancer: ASPREE

Michael O'Riordan

September 27, 2024

Lingering Gaps in CVD Care for Women Spotlighted in British Consensus Statement

News Daily News

Lingering Gaps in CVD Care for Women Spotlighted in British Consensus Statement

September 26, 2024

Medicaid Coverage Improves CV Risk in Some, Post Hoc Analysis Shows

News Daily News

Medicaid Coverage Improves CV Risk in Some, Post Hoc Analysis Shows

September 25, 2024

High Levels of Metals, Particularly Cadmium, Linked to Subclinical CVD

News Daily News

High Levels of Metals, Particularly Cadmium, Linked to Subclinical CVD

Michael O'Riordan

September 23, 2024

Debating a PCI-First Strategy in Stable CAD: ORBITA-2 vs the Unconvinced

News Daily News

Debating a PCI-First Strategy in Stable CAD: ORBITA-2 vs the Unconvinced

Michael O'Riordan

September 20, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.